0001193125-21-113151.txt : 20210412 0001193125-21-113151.hdr.sgml : 20210412 20210412160554 ACCESSION NUMBER: 0001193125-21-113151 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20210407 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20210412 DATE AS OF CHANGE: 20210412 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Homology Medicines, Inc. CENTRAL INDEX KEY: 0001661998 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473468154 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38433 FILM NUMBER: 21820792 BUSINESS ADDRESS: STREET 1: ONE PATRIOTS PARK CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 781-301-7277 MAIL ADDRESS: STREET 1: ONE PATRIOTS PARK CITY: BEDFORD STATE: MA ZIP: 01730 8-K 1 d141110d8k.htm 8-K 8-K
false 0001661998 0001661998 2021-04-07 2021-04-07












Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 7, 2021




(Exact name of registrant as specified in its charter)




Delaware   001-38433   47-3468154

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


One Patriots Park

Bedford, MA

(Address of principal executive offices)   (Zip Code)

(781) 301-7277

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   FIXX   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 7, 2021, the Board of Directors (the “Board”) of Homology Medicines, Inc. (the “Company”) appointed Tim Kelly as Chief Operating Officer of the Company.

Prior to his appointment, Mr. Kelly, 52, served as our Chief Technical Operations Officer from April 2018 to April 2021, where he led the construction of the Company’s internal 25,000-square-foot GMP manufacturing facility, which was completed in 12 months from design to operation, and scaled to a 2,000-liter bioreactor with a HEK293 serum-free suspension system. Prior to that, Mr. Kelly served as our Senior Vice President of Technical Operations from May 2017 to April 2018. Under his leadership, the Company has attracted and grown a highly experienced technical operations team. From January 2017 to May 2017, Mr. Kelly served as Head of Technical Operations at Sarepta Therapeutics, Inc., a biopharmaceutical company. Prior to that, Mr. Kelly spent eight years, from 2009 to 2017, at Shire plc, a biotechnology company, where he served most recently as Senior Vice President and Head of Biologics Operating Unit from May 2016 to January 2017, and prior to that served in roles of increasing responsibility, including Interim Head of Technical Operations from August 2015 to April 2016 and Head of Product Strategy & Planning from 2014 to July 2015. He was previously the Head of Technical Operations at UCB S.A. in Belgium. Mr. Kelly also held roles of increasing responsibility at Biogen Idec, including Senior Director of International Operations. Mr. Kelly holds a B.S. with emphasis in Engineering Mechanics from the United States Air Force Academy and an M.B.A. from Troy University.

In connection with his appointment, on April 7, 2021, the Board granted Mr. Kelly an option to purchase 10,000 shares of the Company’s common stock, with an exercise price of $7.18 per share, the fair market value of a share of the Company’s common stock on the date of grant, which option vests over four years in forty-eight (48) substantially equal installments upon Mr. Kelly’s completion of each full month of service to the Company following April 12, 2021. Also in connection with the appointment, Mr. Kelly’s annual base salary was increased by $16,000 to $435,300 effective as of April 12, 2021.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: April 12, 2021     By:  

/s/ W. Bradford Smith

      W. Bradford Smith
      Chief Financial Officer and Treasurer
EX-101.SCH 2 fixx-20210407.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 fixx-20210407_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 fixx-20210407_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 d141110d8k_htm.xml IDEA: XBRL DOCUMENT 0001661998 2021-04-07 2021-04-07 false 0001661998 8-K 2021-04-07 HOMOLOGY MEDICINES, INC. DE 001-38433 47-3468154 One Patriots Park Bedford MA 01730 (781) 301-7277 false false false false Common Stock, $0.0001 par value per share FIXX NASDAQ true false XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information
Apr. 07, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001661998
Document Type 8-K
Document Period End Date Apr. 07, 2021
Entity Registrant Name HOMOLOGY MEDICINES, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-38433
Entity Tax Identification Number 47-3468154
Entity Address, Address Line One One Patriots Park
Entity Address, City or Town Bedford
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01730
City Area Code (781)
Local Phone Number 301-7277
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol FIXX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( +J C%('04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "Z@(Q2>KWW[.X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>NLG8#E&7"X@32$A, G&+'&^+:-HH,6KW]K1EZX3@ 3C&_O/Y ML^0:H\8NT7/J(B7VE&^&T+198]R*(W/4 !F/%&PNQT0[-O=="I;'9SI M/AA M#P2JJC80B*VS;&$"%G$A"E,[U)C((<+/GZF9H8Y!&HH4,L99"E!F&EB M/ U-#5? !&-*(7\7R"W$N?HG=NZ .">'[)=4W_=EOYISXPX2WIX>7^9U"]]F MMBW2^"M[S:=(6W&9_+JZN]\]"*,J)8OJMI!J)S>Z6NNU>I]621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M +J C%)69F,W5@0 -L0 8 >&PO=V]R:W-H965T&UL ME9A=<^(V%(:OM[]"P_2BG2'Q!P23'<(,(627V01H2+O;=GHA; &:V)97D@/Y M]SV2B4U;A/&T-!_;>0@X'(MX VPEH%\"^E:OT1VY,O[*V. M"%=R7=?K];SKZSZ"=55B7:%B94D\OV6LC@4/[U]\02!Z)43O/(@%DUR8THP( M%'@M#ZYD"S)H__#A0T-%!B5:<,ZP/;$--S4)C#.:U(+A.I_GC_.'^:??R>/D M;CJ>SB;+-IG.QI<(8K]$[)^#.$U#(3,A[50F2PWY(V.10[E!U8FHEAD7OIL@ M=-F:>U0]D@"5%D035, M+ZW@0KY@H)5=>_[_ AV;EI#D6>SJ5Q-<[I9%L!A%&%IE^Q[NV_]&*R8$L"VD M>.5I6)]$7/-QA*%5*X%WUE)0HBV$TK D_,&SDQ.U0='U@HZ+L57+@8<;NAW! M$6SY3J/@ C\%?>]G#*5:%#S#2 >L(_"# ".JU@(/-_&O MDFO-4DA-DN3IP354+14NU+2I\"KO]W"/7HJ8AUSS=$,>H< EIW$M#Z[2R%.Y MO8=;]4(RFQX&,ZS85\#V"_9T\_7ZQ/CA>DUD?F7[/N[1_R&;*I4#61-@@VPC M8.7Z/F[12Q;FTDP_SU^19Z[CVNG7(&)Z:)=_$;ZTR8_NI=DMDHQ*\DKCG)$, MNJJV5*+(1]MUW+"?)8U,Z2W?DI6H+;P&@?OIMV\8267W/F[-9?(F^W!+TPT[ MN4]K$)J-EG>C7S"FRN?]LWQ^DC"Y,5GZ! IZ:XHPHVGMQK]!4,L<';?*Y7W< MI-_)]@1&$ [==O=3;+YKL7"UDU/ .3JJFF/_(S6)4"1F:Q!R+P/0E<5)NFAH MD=G3ZTIH. O;RRVC,#W-"_!\+81^;Y@#&PO9KEMW MDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[< M9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20 MIV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/! M)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FS MX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5 M[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7S MJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41 MP+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS M#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U M(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT, M/O'^8* \^>Q\ETWLJ.?]74_P$4$L# M!!0 ( +J C%*7BKL

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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d141110d8k.htm fixx-20210407.xsd fixx-20210407_lab.xml fixx-20210407_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d141110d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d141110d8k.htm" ] }, "labelLink": { "local": [ "fixx-20210407_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "fixx-20210407_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "fixx-20210407.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "fixx", "nsuri": "http://www.homologymedicines.com/20210407", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d141110d8k.htm", "contextRef": "duration_2021-04-07_to_2021-04-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d141110d8k.htm", "contextRef": "duration_2021-04-07_to_2021-04-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20210407/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0001193125-21-113151-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-113151-xbrl.zip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end